09-15-2017 | Exenatide | EASD 2017 | News
EXSCEL: Near miss for exenatide cardioprotection
The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.
09-13-2017 | GLP-1 agonists | EASD 2017 | News
Incretins research update
One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.